2015年ASCO年会演讲摘要.pptx

APhaseIIIStudy(CheckMate017)br/ofNivolumab(Anti-ProgrammedDeath-1)br/vsDocetaxelinPreviouslyTreatedAdvancedorMetastaticSquamous(SQ)CellNon-Small-CellLungCancer(NSCLC)PresentedByDavidSpigelat2015ASCOAnnualMeeting

DisclosuresPresentedByDavidSpigelat2015ASCOAnnualMeeting

IntroductionPresentedByDavidSpigelat2015ASCOAnnualMeeting

NivolumabMechanismofActionPresentedByDavidSpigelat2015ASCOAnnualMeeting

CheckMate017(NC-StudyDesignPresentedByDavidSpigelat2015ASCOAnnualMeeting

BaselineCharacteristicsPresentedByDavidSpigelat2015ASCOAnnualMeeting

OverallSurvivalPresentedByDavidSpigelat2015ASCOAnnualMeeting

Progression-FreeSurvivalPresentedByDavidSpigelat2015ASCOAnnualMeeting

ObjectiveResponseRatePresentedByDavidSpigelat2015ASCOAnnualMeeting

ResponseCharacteristicsofConfirmedRespondersPresentedByDavidSpigelat2015ASCOAnnualMeeting

OSandPFSbyPD-L1ExpressionPresentedByDavidSpigelat2015ASCOAnnualMeeting

OSbyPD-L1ExpressionPresentedByDavidSpigelat2015ASCOAnnualMeeting

ORRbyPD-L1ExpressionPresentedByDavidSpigelat2015ASCOAnnualMeeting

LCSSAverageSymptomBurdenIndex:br/MeanChangeFromBaselineWhileonTreatmentPresentedByDavidSpigelat2015ASCOAnnualMeeting

TreatmentandSafetySummaryPresentedByDavidSpigelat2015ASCOAnnualMeeting

Treatment-relatedAEs(≥10%ofpatients)PresentedByDavidSpigelat2015ASCOAnnualMeeting

Treatment-relatedSelectAEsPresentedByDavidSpigelat2015ASCOAnnualMeeting

SummaryPresentedByDavidSpigelat2015ASCOAnnualMeeting

Slide19PresentedByDavidSpigelat2015ASCOAnnualMeeting

AcknowledgementsPresentedByDavidSpigelat2015ASCOAnnualMeeting

ReferencesPresentedByDavidSpigelat2015ASCOAnnualMeeting

AbbreviationsPresentedByDavidSpigelat2015ASCOAnnualMeeting